S&P 500
-3.73 -0.17%
Dow Indu
+30.06 +0.17%
-33.35 -0.64%
Crude Oil
+0.15 +0.30%
+3.09 +0.24%
+0.002685 +0.25%
US Dollar
-0.018 -0.02%

This Week's Stock Was Just Released - Projected 14% Gain

Our Stock of the Week was released this morning. Are you on the list?

INO.com's Stock of the Week

If you haven't subscribed to INO's Stock of the Week, you can get this week's pick right now and you'll receive a new pick each and every Tuesday before the opening bell.

An excerpt from today's Stock of the Week:

"Having a well-balanced portfolio is essential for success as an investor. Loading up on small cap stocks or lesser-known brands can add excitement to a portfolio but at the cost of adding more risk than you might want leading to dramatic declines when the market becomes volatile. Making sure you have a solid, large-cap performer in the mix can round out volatility while increasing overall diversity and value to your portfolio.

Right now the tech industry has some of the fast growing companies in the stock market. Even large-cap stocks in tech have the ability to outperform the broader indexes. This company has been consistently breaking new ground in the technology space and its name is synonymous with innovation making it best in breed..."

What to know what this stock is? We'll send our full analysis to you right now.

Our analyst, Daniel Cross, projects that this well-known, highly-liquid stock is fair valued at 16% above the current price.

Send me this week's stock.

We hope you'll like this complimentary service from INO.com.

The INO.com Team

Is The Market Waiting Until Next Week To Make A Move?

Hello MarketClub members everywhere. Next week, Amazon.com (NASDAQ:AMZN), Apple Inc. (NASDAQ:AAPL) And Alphabet Inc. (NASDAQ:GOOG) all report earnings. This could be the catalyst to get the market out of the doldrums and the sideways pattern that I've been talking about for what seems like ever.

Yesterday Microsoft Corporation (NASDAQ:MSFT) announced its earnings a beat 76 cents vs. 68 estimates, that was enough to push the stock up above its 1999 highs of $59.97 in after-her-hour ours trading. It would appear that the turnaround efforts for Microsoft are on track under the guidance of Microsoft's CEO Satya Nadella.

The market has been remarkably quiet with most of the noise coming out of the presidential campaign this week.

Once again, MarketClub's Trade Triangles point the way to successful trading. If you are not tracking the Trade Triangles, you may decide to do so after looking at how they are positioned in many of the markets.

Looking at the major markets here are the minuscule changes so far this week (Thursday Closes). [Read more...]

Preview Issue #4 - Mylan Capitulates, M&A Activity Heats Up and the Negative Political Backdrop

INO Health & Biotech Stock Guide

Preview Issue #3 - October 13th, 2016


Mylan has been a whipping post as of late over its aggressive pricing increases regarding its EpiPen which uses an auto-injection of epinephrine to treat severe allergic reactions in primarily school age children. As a result, Mylan has ostensibly capitulated in the face of public and governmental scrutiny regarding its EpiPen pricing with implementing plans to offer a generic version and a $465 million settlement with the U.S. department of Justice to appease the public and improve its company image. The relentless congressional grilling on Capitol Hill and public backlash against Mylan and its CEO looks to have spurred the company into offering a generic and cheaper version of its EpiPen as well as providing more EpiPen via its access programs. However, congressional leaders continue to criticize Mylan over its alleged misrepresentation of profits and under paying Medicare in rebates. Congressional leaders stated that Mylan was dishonest when it incorrectly applied a statutory U.S. tax rate on its EpiPen revenue. The company is technically based ex-U.S. and thus pays a lower tax rate. Furthermore, the company has been accused of misclassifying the EpiPen to game the Medicaid Drug Rebate Program. Mylan has been reportedly paying a 13% rebate that is reserved for generics while the brand name EpiPen should be at a minimum of a 21% rebate rate. Congressional leaders have vowed to recoup the difference over the past five years Medicaid has spent on EpiPens (total Medicaid spending from 2011 through 2015 was reported to be $960 million for the EpiPen). To this end, Mylan just settled a $465 million lawsuit regarding this egregious misclassification under the Medicaid Drug Rebate Program. This negative publicity along with continuous political attacks has been a major overhang impacting biotech stocks. This public and contentious battle with government officials and the general public doesn’t bode well for the entire healthcare cohort. With ongoing presidential debates and political posturing still occurring, this will likely continue to be a source of volatility. Buying opportunities may present themselves throughout the sector due to extraneous political rhetoric regarding the drug pricing debate and the entire drug supply chain dynamics.


[Read more...]

Preview Issue #3 - Pharma Acquisitions Change The Game

INO Health & Biotech Stock Guide

Preview Issue #3 - Sept 28th, 2016


Myan’s CEO is grilled by congressional leaders on Capitol Hill, Allergan (NYSE:AGN) and Johnson & Johnson (NYSE:JNJ) step up merger and acquisition activity and the presidential debates are underway. Mylan has dominated the pharma news headlines recently over its aggressive pricing increases regarding its EpiPen which uses an auto-injection of epinephrine to treat severe allergic reactions, particularly deadly in school age children. Since Mylan acquired the product in 2007, and the “list” price increased from $100 in 2008 to its current “list” price of ~$600. Elijah Cummings [Read more...]

Preview Issue #2 - Mylan, Walgreens & IBB

INO Health & Biotech Stock Guide

Preview Issue #2 - Sept 21st, 2016


Hillary Clinton has thrusted the drug pricing debate onto center stage once again after calling out Mylan for its aggressive price increases over the past decade for its EpiPen. The EpiPen uses an auto-injection of epinephrine to treat severe allergic reactions, particularly deadly in school age children. Mylan acquired the product in 2007, and the “list” price increased from $100 in 2008 to its current “list” price of ~$600. Hillary Clinton was quoted as stating:

[Read more...]

© Copyright INO.com, Inc. All Rights Reserved.